Monogram Provides Regulatory Update Following Meeting with FDAMonogram Provides Regulatory Update Following Meeting with FDA

Monogram Provides Regulatory Update Following Meeting with FDA

1 year ago

510(k) Submission with FDA Accelerated for Early Second Half of 2024 AUSTIN, TX / ACCESSWIRE / May 1, 2024 /…

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationAltamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

1 year ago

Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery  Treatment of rheumatoid…

Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionAileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

1 year ago

Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from…

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose LevelSELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

1 year ago

- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and…

NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness MonthNeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month

NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month

1 year ago

The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearanceMALVERN, Pa., May…

Psyched Wellness Closes Final US$2.5M Tranche of Its Non-Brokered Private Placement for a Total of US$7.5M with Gotham Green Partners and Provides Corporate UpdatePsyched Wellness Closes Final US$2.5M Tranche of Its Non-Brokered Private Placement for a Total of US$7.5M with Gotham Green Partners and Provides Corporate Update

Psyched Wellness Closes Final US$2.5M Tranche of Its Non-Brokered Private Placement for a Total of US$7.5M with Gotham Green Partners and Provides Corporate Update

1 year ago

Toronto, Ontario--(Newsfile Corp. - May 1, 2024) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or…

FendX to Present at Sidoti Virtual Investor Conference on May 9, 2024FendX to Present at Sidoti Virtual Investor Conference on May 9, 2024

FendX to Present at Sidoti Virtual Investor Conference on May 9, 2024

1 year ago

Oakville, Ontario--(Newsfile Corp. - May 1, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or…

LivaNova Reports First-Quarter 2024 ResultsLivaNova Reports First-Quarter 2024 Results

LivaNova Reports First-Quarter 2024 Results

1 year ago

LONDON--(BUSINESS WIRE)--#cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024…

MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3

MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3

1 year ago

VANCOUVER, BC / ACCESSWIRE / May 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), is pleased to…

Bioz and Copan Diagnostics Release AI-Based Citation Tools for ResearchersBioz and Copan Diagnostics Release AI-Based Citation Tools for Researchers

Bioz and Copan Diagnostics Release AI-Based Citation Tools for Researchers

1 year ago

PALO ALTO, CA / ACCESSWIRE / May 1, 2024 / Bioz, Inc., a Bay Area-based AI company, and Copan Diagnostics,…